Treatment Outcomes Among Pregnant Patients With Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-analysis.

Authors:

Kefyalew Addis Alene Megan B Murray Brittney J van de Water Mercedes C Becerra Kendalem Asmare Atalell Mark P Nicol Archie C A Clements

JAMA Netw Open 2022 06 1;5(6):e2216527. Epub 2022 Jun 1.

Telethon Kids Institute, Nedlands, Western Australia, Australia.

Importance: The management of multidrug-resistant tuberculosis (MDR-TB) during pregnancy is challenging, yet no systematic synthesis of evidence has accurately measured treatment outcomes.

Objective: To systematically synthesize treatment outcomes and adverse events among pregnant patients with MDR-TB.

Data Sources: PubMed, Scopus, Web of Science, and ProQuest were searched from the inception of each database through August 31, 2021.

Study Selection: Studies containing cohorts of pregnant patients with a defined treatment outcome were eligible.

Data Extraction And Synthesis: Independent reviewers screened studies and assessed the risk of bias. The study followed the Preferring Reporting Items for Systematic Review and Meta-analyses reporting guideline. Meta-analysis was performed using random-effects models. The sources of heterogeneity were explored through metaregression.

Main Outcomes And Measures: The primary outcome was the proportion of patients with each treatment outcome (including treatment success, death, loss to follow-up, and treatment failure), and the secondary outcomes included the proportion of patients experiencing adverse events during pregnancy.

Results: In this systematic review and meta-analysis, 10 studies containing 275 pregnant patients with available data on treatment outcomes were included. The pooled estimate was 72.5% (95% CI, 63.3%-81.0%) for treatment success, 6.8% (95% CI, 2.6%-12.4%) for death, 18.4% (95% CI, 13.1%-24.2%) for loss to follow-up, and 0.6% (95% CI, 0.0%-2.9%) for treatment failure. Treatment success was significantly higher in studies in which the proportion of patients taking linezolid was greater than the median (20.1%) compared with studies in which this proportion was lower than the median (odds ratio, 1.22; 95% CI, 1.05-1.42). More than half of the pregnant patients (54.7%; 95% CI, 43.5%-65.4%) experienced at least 1 type of adverse event, most commonly liver function impairment (30.4%; 95% CI, 17.7%-45.7%), kidney function impairment (14.9%; 95% CI, 6.2%-28.3%), hypokalemia (11.9%; 95% CI, 3.9%-25.6%), hearing loss (11.8%; 95% CI, 5.5%-21.3%), gastrointestinal disorders (11.8%; 95% CI, 5.2%-21.8%), psychiatric disorders (9.1%; 95% CI, 2.5%-21.6%), or anemia (8.9%; 95% CI, 3.6%-17.4%). The pooled proportion of favorable pregnancy outcomes was 73.2% (95% CI, 49.4%-92.1%). The most common types of adverse pregnancy outcomes were preterm birth (9.5%; 95% CI, 0.0%-29.0%), pregnancy loss (6.0%; 95% CI, 1.3%-12.9%), low birth weight (3.9%; 95% CI, 0.0%-18.7%), and stillbirth (1.9%; 95% CI, 0.1%-5.1%). Most of the studies had low-quality (3 studies) or medium-quality (4 studies) scores.

Conclusions And Relevance: In this systematic review and meta-analysis, high treatment success and favorable pregnancy outcomes were reported among pregnant patients with MDR-TB. Further research is needed to design shorter, more effective, and safer treatment regimens for pregnant patients with MDR-TB.

Download full-text PDF	Source
http://dx.doi.org/10.1001/jamanetworkopen.2022.16527	DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187956	PMC

June 2022

Publication Analysis

Top Keywords

Keyword Occurance

Similar Publications

Risk of preeclampsia in patients with symptomatic COVID-19 infection.

Authors:

Melanie Tran Vivien Alessandrini Jacques Lepercq François Goffinet

J Gynecol Obstet Hum Reprod 2022 Aug 15:102459. Epub 2022 Aug 15.

Port-Royal Maternity Hospital, Université Paris-Cité, Groupe hospitalier Cochin Broca Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris, 123 Boulevard de Port Royal, 75014 Paris, France; FHU PREMA (Fédération Hospitalo-Universitaire Combattre la prématurité), Université Paris-Cité, 123 Boulevard de Port Royal, 75014 Paris, France; Obstetrical, Perinatal and Pediatric Epidemiology (Epopé) Research Team, Center of Research in Epidemiology and Statistics (CRESS), INSERM U1153, 53 avenue de l'Observatoire, 75014, Paris, France.

Objectives: Recent studies suggest an association between COVID-19 infection during pregnancy and preeclampsia. Nonetheless, these studies are subject to numerous biases. We compared the onset of preeclampsia in a group with symptomatic COVID-19 during pregnancy to that in a group whose non-exposure to the virus was certain, in a center where pregnancy management was identical in both groups. Read More

View Article and Full-Text PDF

August 2022

Similar Publications

Evaluating the Effects of Ertapenem and Meropenem on Tacrolimus.

Authors:

Samantha Elledge Kyle Klindworth Jennifer Guy Lindsey DeZotell Ashley K Holmes

J Pharm Pract 2022 Aug 18:8971900221117627. Epub 2022 Aug 18.

Pharmacy Department, Saint Luke's Hospital, Kansas City, MO, USA.

Purpose: Further elucidate the potential drug interaction between tacrolimus and carbapenems in order to appropriately maintain the balance between infection treatment and therapeutic immunosuppression.

Methods: This study was a retrospective evaluation of solid organ transplant recipients on a stable dose of tacrolimus who received either ertapenem or meropenem. Patients were excluded if they had acute kidney injury, acute liver failure, concomitant initiation of medications that interact with tacrolimus, or were pregnant. Read More

View Article and Full-Text PDF

August 2022

Similar Publications

MiR-30a-3p Targeting FLT1 Modulates Trophoblast Cell Proliferation in the Pathogenesis of Preeclampsia.

Authors:

Yuping Wang Lanlan Wang Xiaoyan Yu Wenwen Gong

Horm Metab Res 2022 Aug 18. Epub 2022 Aug 18.

Department of Obstetrics and Gynecology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.

Preeclampsia (PE) may pose significant adverse effects on pregnant women. Dysregulation of angiogenesis, trophoblast invasion, and proliferation are known to be associated with PE development and progression. Fms related tyrosine kinase 1 (FLT1), an anti-angiogenic factor, is consistently upregulated in PE patients. Read More

View Article and Full-Text PDF

August 2022

Similar Publications

European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy.

J Eur Acad Dermatol Venereol 2022 Sep;36(9):1409-1431

Pediatric Dermatology Unit, Heim Pál National Children's Institute Budapest, Budapest, Hungary.

The evidence- and consensus-based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. Four consensus conferences were held between December 2020 and July 2021. Twenty-nine experts (including clinicians and patient representatives) from 12 European countries participated. Read More

View Article and Full-Text PDF

September 2022

Similar Publications

Developing a Core Outcome Set for the Evaluation of Antibiotic Use in Prelabor Rupture of Membranes: A Systematic Review and Semi-Structured Interview.

Authors:

Dan Liu Lin Wu Jiefeng Luo Siyu Li Yan Liu Chuan Zhang Linan Zeng Qin Yu Lingli Zhang

Front Pharmacol 2022 1;13:915698. Epub 2022 Aug 1.

Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China.

Prelabor rupture of membranes (PROM) is associated with maternal and neonatal infections. Although guidelines suggest prophylactic antibiotics for pregnant women with PROM, the optimal antibiotic regimen remains controversial. Synthesizing the data from different studies is challenging due to variations in reported outcomes. Read More

View Article and Full-Text PDF

August 2022

Similar Publications

}

Search Our Scientific Publications & Authors